131532
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- age_years
- 25
- fusion
- ZFTA_RELA
- e1_e2
- E2
- umap1_2d
- -5.795270085
- umap2_2d
- 0.263587971
- umap1_3d
- 0.378207715
- umap2_3d
- 3.523439573
- umap3_3d
- 0.020668433
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.490
- INTERFERON_GAMMA_RESPONSE+0.480
- IL6_JAK_STAT3_SIGNALING+0.460
- HEDGEHOG_SIGNALING+0.340
- PEROXISOME+0.310
- ALLOGRAFT_REJECTION+0.290
- BILE_ACID_METABOLISM+0.290
- ADIPOGENESIS+0.280
- INFLAMMATORY_RESPONSE+0.280
- XENOBIOTIC_METABOLISM+0.280
Top 10 suppressed
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.400
- MYC_TARGETS_V1-0.310
- MYC_TARGETS_V2-0.290
- ANDROGEN_RESPONSE-0.210
- MITOTIC_SPINDLE-0.180
- CHOLESTEROL_HOMEOSTASIS-0.170
- MTORC1_SIGNALING-0.130
- SPERMATOGENESIS-0.120
- UV_RESPONSE_DN-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_KX6J8TRK | pilocytic astrocytoma | — | 0.857 |
| 2 | BS_V3REENH9 | pilocytic astrocytoma | — | 0.844 |
| 3 | 88326 | EPN | Supratentorial EPN | 0.840 |
| 4 | SRR10900573 | — | — | 0.831 |
| 5 | BS_PQ6QEVE8 | Ganglioglioma | — | 0.825 |
| 6 | BS_3G3KWY18 | low-grade glioma | — | 0.823 |
| 7 | BS_FJZPQZ2C | pleomorphic xanthoastrocytoma(PXA) | — | 0.812 |
| 8 | BS_JVA2NQFF | pilocytic astrocytoma | — | 0.812 |
| 9 | TCGA-BH-A0B6-01A-11R-A19W-07 | — | D | 0.809 |
| 10 | TCGA-05-4425-01A-01R-1755-07 | — | cohortA1 | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| PEROXISOME | 0.310 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.120 | Inavolisib | — uncovered |